Blog / semaglutide
CagriSema Research Explained: What the REDEFINE Trials Show and What to Track
A plain guide to CagriSema research: what the REDEFINE trials reported, what is still unknown, and what to track in a peptide tracker.
By Peppy Team6 min read
CagriSema is one of the most talked about names in weight research right now. It pairs two peptides in one weekly injection, and large trials have reported results that got a lot of attention. If you keep a peptide tracker, or you are simply trying to understand the headlines, it helps to know what the research actually measured and what it did not.
This guide walks through the main CagriSema studies in plain language. It also covers the records that make conversations with your provider easier if CagriSema, or any combination treatment, ever becomes part of your plan. Nothing here is a suggestion to use it. That call belongs to a licensed healthcare provider who knows your history.
What CagriSema is
CagriSema is the name researchers use for cagrilintide and semaglutide given together. The REDEFINE 3 design paper describes it as a fixed-dose combination of an amylin receptor agonist (cagrilintide) and a GLP-1 receptor agonist (semaglutide), given under the skin once a week.
Two hormones, two pathways
Semaglutide copies the action of GLP-1, a gut hormone involved in appetite and blood sugar. Many readers already know it as the active ingredient in Ozempic and Wegovy, and plenty already log it in a semaglutide tracker.
Cagrilintide is a long-acting version of amylin, a different hormone. The idea behind the pairing is simple. If two hormones act on appetite through different pathways, using both might add to what one does alone. That is a hypothesis the trials were designed to test, not a promise.
Why this matters for record-keeping
A combination means two active ingredients in one shot. That can make your notes less obvious than with a single peptide. When you look back at your log months later, you want to know exactly what each entry was, not guess.
What the REDEFINE 1 trial reported
REDEFINE 1 was a phase 3a trial published in the New England Journal of Medicine in 2025. You can read the REDEFINE 1 abstract on PubMed.
Who took part
The trial enrolled 3,417 adults without diabetes. Everyone had either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. People were randomly assigned to CagriSema, semaglutide alone, cagrilintide alone, or placebo. All groups also received lifestyle support, and the trial ran for 68 weeks.
What the researchers found
The authors reported an estimated average body weight change of about 20.4% with CagriSema, compared with about 3.0% with placebo, over 68 weeks. People in the CagriSema group were also more likely to reach weight loss targets of 5%, 20%, 25% and 30%.
Side effects were common. Gastrointestinal events such as nausea, vomiting, diarrhea, constipation or abdominal pain were reported by 79.6% of the CagriSema group and 39.9% of the placebo group. The authors described them as mainly short-lived and mild to moderate.
Keep in mind that these are averages across thousands of people. Individual results in the trial varied, and any single person's experience can look very different.
What the REDEFINE 2 trial reported
REDEFINE 2 looked at a different group: adults with type 2 diabetes and a BMI of 27 or higher. Its results were published in the same NEJM issue, and the REDEFINE 2 abstract on PubMed lists the details.
The main numbers
The trial included 1,206 people across 12 countries for 68 weeks. The estimated average weight change was about 13.7% with CagriSema and 3.4% with placebo. The authors also reported that 73.5% of the CagriSema group reached an HbA1c of 6.5% or lower, compared with 15.9% on placebo.
Gastrointestinal events were again more frequent with CagriSema, reported by 72.5% compared with 34.4% on placebo.
Why the numbers differ between trials
Weight change in REDEFINE 2 was smaller than in REDEFINE 1. The two trials enrolled different people, with and without type 2 diabetes, so their results should not be compared as if they were one study. Your provider can explain how findings like these relate to your own health.
What is still being studied
Weight is only one outcome. Researchers also want to know about heart health over the long term. The REDEFINE 3 trial is testing that question in 7,076 adults with established cardiovascular disease, comparing CagriSema with placebo on major heart events. The REDEFINE 3 design paper on PubMed describes the setup and the people enrolled. Its outcome results were not part of that paper.
Reading the research with care
A few points are worth holding onto when you read about CagriSema:
- The main trials were funded by the manufacturer, which is common for phase 3 research.
- Trial participants had regular check-ins and lifestyle support, which is not the same as everyday life.
- The trials used fixed doses chosen by the researchers. Those choices are not guidance for anyone outside the study.
- Approval status and availability can change. Your provider is the right person to explain where things stand for you.
What to track if a combination is part of your plan
If your provider prescribes CagriSema or another combination peptide, a clear log helps you and your provider see the full picture. These are the records worth keeping.
Each dose, exactly as given
Write down the date, the time and the dose your provider gave you for each injection. With a combination, note the product name so you never confuse it with a single-ingredient medicine. A dose history like the one in Peppy's dose log keeps that in one place with on-time and missed doses marked.
Step changes
Combination treatments in trials were usually increased in steps over several weeks. If your provider sets steps for you, record each one with its start date. A titration schedule record makes it easy to see which step you were on when something changed.
Side effects next to doses
Both REDEFINE trials reported stomach-related side effects as the most common. Logging how you felt, with a simple mild, moderate or severe rating, next to the dose date gives your provider useful context. Do not try to read meaning into the pattern yourself. Bring it to your appointment and let your provider interpret it.
Weight on a regular schedule
Weigh yourself at a consistent time, such as the same morning each week. A weight tracking chart shows the trend more clearly than scattered numbers in a notes app.
Vial or pen details
If your medication comes in a vial, note the strength printed on the label, the amount of water added (if it was a powder) and the date it was mixed. The free Peppy peptide calculator turns the vial strength, the water added and the dose your provider gave you into the units to draw on a U-100 insulin syringe. It only converts the numbers you enter and does not suggest a dose.
Keeping a record in Peppy
Peppy is a peptide tracker app for iPhone that keeps doses, steps, side effects and weight together. You enter the dose your provider gave you, and it shows that dose in units on your syringe each time you log. It also has dose reminders and a full history you can scroll through before an appointment. There is no account to create, and your data stays on your iPhone and your own iCloud backup.
The short version
CagriSema combines an amylin analog with semaglutide. In the REDEFINE 1 and REDEFINE 2 trials, researchers reported larger average weight changes than placebo, along with frequent but mostly mild to moderate stomach side effects. Heart outcome research is still underway.
Whether any of this applies to you is a conversation for your licensed healthcare provider. What you can control is the quality of your records. A steady, honest log of doses, steps, side effects and weight gives that conversation a much better starting point.
More from the blog

semaglutide6 min read
Semaglutide Benefits: What the Evidence Says and How to Track Your Progress
A plain guide to semaglutide benefits backed by FDA approvals and research, what they do not promise, and how to track your own progress with your provider.
- semaglutide
- glp 1
- weight

semaglutide6 min read
Semaglutide Tracker: How to Log Doses, Weight and Side Effects Week by Week
A practical semaglutide tracker guide: what to log at every weekly shot, how to track weight and side effects, and what to bring to your provider.
- semaglutide
- glp 1
- dose log

glp 16 min read
What Orforglipron Research Shows About Oral GLP-1 Pills and What to Track
A plain guide to the ATTAIN-1 and ACHIEVE-1 orforglipron trials, how a daily GLP-1 pill differs from injectables, and what to record.
- glp 1
- dose log
- side effects
